LISAvienna to celebrate the launch of KHAN-I fund: € 60 million for early stage drug development

Friday, 27 September 2019 01:19 Written by 

LISAvienna’s co-owner Austria Wirtschaftsservice invests in the KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I) to foster translational research in Austrian life sciences. Exciting new findings and hypotheses will undergo systematic and professional testing and validation.


The KHAN-I fund focuses on innovative projects that have a clear potential for creating new therapeutic modalities in indications with an unmet medical need. The results are prototypes of new drugs that have a high chance for further development and commercialization. A total of € 60 million is available for promising new drug discovery projects inspired by cutting-edge research. The European Investment Fund contributes half the money. In Austria, the Austria Wirtschaftsservice with funds provided by the Österreich-Fonds and the Federal Ministry for Digital and Economic Affairs, and the Max Planck Foundation in Germany, act as co-investors.


Proposals can be submitted as of now. In Austria, the newly founded wings4innovation GmbH, located in Vienna, is your contact point.


Researchers whose ideas and approaches are taken to the next level by KHAN-I will be on board as collaboration partners. Projects will be managed by the fund and the necessary experiments will be carried out in collaboration with experienced partners such as the Lead Discovery Center and contract research organizations. In case of positive results, drug candidates will be out-licensed or become the cornerstone of start-ups. Researchers and their home scientific institutions will have a share in the fund’s proceeds. The biggest benefit however is with the patients: At the end of the day, our society will benefit much faster from research than is the case today.


Download further details at


Published in Mitgliedsnews